Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation
- PMID: 28709886
- DOI: 10.1016/j.juro.2017.07.010
Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation
Abstract
Purpose: We evaluated the therapeutic success rate, changes in quality of life and safety of sacral neuromodulation 5 years after InterStim™ implantation. Included in study were subjects with bothersome symptoms of overactive bladder, including urinary urge incontinence and/or urgency-frequency, in whom at least 1 anticholinergic medication failed and 1 medication had not been tried.
Materials and methods: Therapeutic success was defined as a urinary urge incontinence or urgency-frequency response of 50% or greater improvement in average leaks or voids per day, or return to normal voiding, defined as fewer than 8 voids per day. Quality of life was evaluated by ICIQ-OABqol (International Consultation on Incontinence Modular Questionnaire). Safety was evaluated through adverse events.
Results: Of the 340 subjects who completed the test stimulation 272 had an implant, of whom 91% were female. Mean age was 57 years. At baseline 202 subjects with urinary urge incontinence had a mean ± SD of 3.1 ± 2.7 leaks per day and 189 with urgency-frequency had a mean of 12.6 ± 4.5 voids per day. The 5-year therapeutic success rate was 67% (95% CI 60-74) using modified completers analysis and 82% (95% CI 76-88) using completers analysis. Subjects with urinary urge incontinence had a mean reduction from baseline of 2.0 ± 2.2 leaks per day and subjects with urgency-frequency had a mean reduction of 5.4 ± 4.3 voids per day (each completers analysis p <0.0001). Subjects showed improvement in all ICIQ-OABqol measures (p <0.0001). The most common device related adverse events were an undesirable change in stimulation in 60 of the 272 subjects (22%), implant site pain in 40 (15%) and therapeutic product ineffectiveness in 36 (13%).
Conclusions: This multicenter study shows that sacral neuromodulation had sustained efficacy and quality of life improvements, and an acceptable safety profile through 5 years in subjects with overactive bladder.
Keywords: electrodes; implanted; overactive; quality of life; urinary bladder; urinary incontinence.
Copyright © 2018 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Comment in
-
Editorial Comment.J Urol. 2018 Jan;199(1):236. doi: 10.1016/j.juro.2017.07.103. Epub 2017 Sep 29. J Urol. 2018. PMID: 28964740 No abstract available.
Similar articles
-
Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder.Neurourol Urodyn. 2016 Feb;35(2):246-51. doi: 10.1002/nau.22707. Epub 2014 Dec 24. Neurourol Urodyn. 2016. PMID: 25546568 Clinical Trial.
-
Three-year Follow-up Results of a Prospective, Multicenter Study in Overactive Bladder Subjects Treated With Sacral Neuromodulation.Urology. 2016 Aug;94:57-63. doi: 10.1016/j.urology.2016.04.024. Epub 2016 Apr 27. Urology. 2016. PMID: 27131966
-
A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study.Neurourol Urodyn. 2019 Feb;38(2):689-695. doi: 10.1002/nau.23892. Epub 2018 Dec 28. Neurourol Urodyn. 2019. PMID: 30592526
-
The role of electrical stimulation techniques in the management of the male patient with urgency incontinence.Curr Opin Urol. 2014 Nov;24(6):560-5. doi: 10.1097/MOU.0000000000000108. Curr Opin Urol. 2014. PMID: 25144143 Review.
-
Role of sacral neuromodulation in modern urogynaecology practice: a review of recent literature.Int Urogynecol J. 2018 Aug;29(8):1081-1091. doi: 10.1007/s00192-017-3546-6. Epub 2018 Jan 4. Int Urogynecol J. 2018. PMID: 29302716 Review.
Cited by
-
Closed-loop sacral neuromodulation for bladder function using dorsal root ganglia sensory feedback in an anesthetized feline model.Med Biol Eng Comput. 2022 May;60(5):1527-1540. doi: 10.1007/s11517-022-02554-8. Epub 2022 Mar 29. Med Biol Eng Comput. 2022. PMID: 35349032 Free PMC article.
-
Sacral neuromodulation for female pelvic floor disorders.Arab J Urol. 2019 Apr 18;17(1):14-22. doi: 10.1080/2090598X.2019.1589930. eCollection 2019 Mar. Arab J Urol. 2019. PMID: 31258941 Free PMC article. Review.
-
Update on the management of overactive bladder.Ther Adv Urol. 2021 Aug 31;13:17562872211039034. doi: 10.1177/17562872211039034. eCollection 2021 Jan-Dec. Ther Adv Urol. 2021. PMID: 34484427 Free PMC article. Review.
-
A Five-Year Retrospective Study on the Clinical Outcomes of Sacral Nerve Stimulation for Neuromodulation of the Lower Urinary Tract in a Tertiary Hospital.Cureus. 2024 Nov 13;16(11):e73626. doi: 10.7759/cureus.73626. eCollection 2024 Nov. Cureus. 2024. PMID: 39677101 Free PMC article.
-
Reprogramming Sacral Neuromodulation for Sub-Optimal Outcomes: Evidence and Recommendations for Clinical Practice.Neuromodulation. 2021 Oct;24(7):1247-1257. doi: 10.1111/ner.13494. Epub 2021 Jul 15. Neuromodulation. 2021. PMID: 34264542 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical